NCT00393029 2011-08-15Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered LymphocytesNational Institutes of Health Clinical Center (CC)Phase 2 Completed12 enrolled 10 charts